In patients with PD-L1 positive (PD-L1 1% or more) NSCLC, the combination of IPI+anti-PD-1 has also shown better OS compared to chemotherapy (median OS, 17.1 months versus 14.9 months) (31), and IPI+anti-PD-1 combined with chemotherapy (2 cycles) showed superior overall survival compared to chemotherapy alone, regardless of PD-L1 expression (median OS, 15.6 months versus 10.9 months) (32). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.